The Effect of Mild or Moderate Hepatic Impairment (cirrhosis) on the Pharmacokinetics of Zileuton

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1995 Jan 1

PMID 8620671

Citations 2

Authors

W M Awni

J H CAVANAUGH

R A Braeckman

S Y Chu

K J Patterson

J M MACHINIST

G R Granneman

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetics of zileuton and its R(+) and S(-) glucuronide metabolites were determined after single and multiple (400mg every 8 hours) oral dose administration in healthy subjects (n = 5) and patients with mild or moderate hepatic impairment (cirrhosis; n = 8). The clearance of total zileuton (unbound plus bound to plasma proteins) in patients with hepatic impairment (approximately 350 ml/min) was approximately half than in healthy subjects (approximately 670 ml/min), with similar values in patients with mild or moderate cirrhosis. However, the clearance of unbound zileuton in patients with moderate hepatic impairment was nearly half that in patients with mild hepatic impairment, and one quarter that in healthy subjects. On the basis of these findings, it may be necessary to reduce the dose in patients with impaired hepatic function to maintain levels similar to those in healthy subjects.

Citing Articles

Benefit-risk assessment of antileukotrienes in the management of asthma.

Garcia-Marcos L, Schuster A, Perez-Yarza E Drug Saf. 2003; 26(7):483-518.

PMID: 12735786 DOI: 10.2165/00002018-200326070-00004.

A risk-benefit assessment of antileukotrienes in asthma.

Smith L Drug Saf. 1998; 19(3):205-18.

PMID: 9747667 DOI: 10.2165/00002018-199819030-00004.

References

Braeckman R, Granneman G, Locke C, MACHINIST J, Cavannaugh J, Awni W . The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:42-8. DOI: 10.2165/00003088-199500292-00007. View

Granneman G, Braeckman R, Erdman K . Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography. Clin Pharmacokinet. 1995; 29 Suppl 2:1-8. DOI: 10.2165/00003088-199500292-00003. View

Albers I, Hartmann H, BIRCHER J, Creutzfeldt W . Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol. 1989; 24(3):269-76. DOI: 10.3109/00365528909093045. View

Knapp H . Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990; 323(25):1745-8. DOI: 10.1056/NEJM199012203232506. View

Carter G, Young P, Albert D, Bouska J, Dyer R, Bell R . 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991; 256(3):929-37. View

Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G, Reyes E . Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol. 1992; 87(3):342-6. View

Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P . The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990; 323(25):1740-4. DOI: 10.1056/NEJM199012203232505. View

Batt D . 5-lipoxygenase inhibitors and their anti-inflammatory activities. Prog Med Chem. 1992; 29:1-63. DOI: 10.1016/s0079-6468(08)70004-3. View

Sweeny D, Bouska J, Machinist J, Bell R, Carter G, Cepa S . Glucuronidation of zileuton (A-64077) by human hepatic microsomes. Drug Metab Dispos. 1992; 20(2):328-9. View

10.

Sirois P, Borgeat P, Lauziere M, Dube L, Rubin P, Kesterson J . Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Agents Actions. 1991; 34(1-2):117-20. DOI: 10.1007/BF01993254. View

11.

Bell R, Young P, Albert D, Lanni C, Summers J, BROOKS D . The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol. 1992; 14(3):505-10. DOI: 10.1016/0192-0561(92)90182-k. View

12.

Rubin P, Dube L, Braeckman R, Swanson L, Hansen R, Albert D . Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Agents Actions Suppl. 1991; 35:103-16. View

13.

Wong S, Awni W, CAVANAUGH J, Locke C, Dube L . The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:9-21. DOI: 10.2165/00003088-199500292-00004. View

14.

Awni W, Braeckman R, Granneman G, Witt G, Dube L . Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:22-33. DOI: 10.2165/00003088-199500292-00005. View

15.

Hui K, TAYLOR I, Taylor G, Rubin P, Kesterson J, Barnes N . Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 1991; 46(3):184-9. PMC: 463027. DOI: 10.1136/thx.46.3.184. View

16.

Lewis R, Austen K, Soberman R . Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990; 323(10):645-55. DOI: 10.1056/NEJM199009063231006. View

17.

MACHINIST J, Kukulka M, Bopp B . In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin Pharmacokinet. 1995; 29 Suppl 2:34-41. DOI: 10.2165/00003088-199500292-00006. View